Status:
COMPLETED
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents ...
Eligibility Criteria
Inclusion
- Adults with type 2 diabetes using Lantus® (insulin glargine) as their basal insulin, not at glycemic goal.
Exclusion
- lung disease
- current smoking or discontinued smoking within past 6 months
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT00348374
Start Date
June 1 2006
End Date
August 1 2008
Last Update
March 16 2010
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-307
2
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
3
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006-2850
4
Pfizer Investigational Site
Malvern, Arkansas, United States, 72104